- Aug 5
- 8 min read
Key Takeaways |
A 70-year-old international patient with relapsed multiple myeloma received BCMA-targeted CAR-T cell therapy at a top-ranked 3A-grade hospital in Xi'an, China — and saw his disease burden drop significantly, with the medical team reporting effective disease control after treatment. |
This wasn't his first attempt. He first sought CAR-T treatment at the same hospital in 2016, but didn't meet that trial's eligibility criteria at the time. He relapsed twice in the years that followed before finally becoming eligible for the now-commercially approved therapy. |
The hospital has one of China's longest CAR-T track records for this exact disease — it was one of four sites nationwide in the original first-in-human trial (2016 onward) of the BCMA CAR-T product that this patient ultimately received, which went on to earn FDA Breakthrough Therapy Designation in 2019. |
Introduction
Multiple myeloma is a cancer of plasma cells that accounts for roughly 13% of blood cancers. Most patients eventually relapse no matter how well they initially respond to treatment, and for a subset of patients — especially those who've already gone through multiple lines of therapy — options become genuinely limited. BCMA-targeted CAR-T cell therapy has changed that picture globally in the past several years, offering meaningful, sometimes durable responses even in heavily pretreated patients.
This case is notable for two reasons at once: it's a strong clinical result in a genuinely difficult disease, and it's also a real story of an international patient — a 70-year-old man from Kyrgyzstan — who traveled to China specifically because the treatment he needed wasn't accessible to him at home. For readers evaluating whether China is a credible destination for advanced cell therapy, this is the kind of access story that matters as much as the clinical data — it sits alongside other documented cases in our library, including a pediatric leukemia CAR-T case and a bone-metastatic lymphoma case. For the fuller landscape of CAR-T availability and cost in China, see our complete 2026 guide to CAR-T treatment in China.
The Patient's Journey Before This Treatment
Patient: a 70-year-old man from Kyrgyzstan, involved in trade cooperation with China
Diagnosis: multiple myeloma, battled for years with recurring relapses
Treatment history: prior treatment failed to bring lasting control; disease repeatedly recurred, with worsening quality of life
First contact with CAR-T (2016): he initially traveled to seek CAR-T treatment at this hospital when it was still in early clinical trials, but did not meet that trial's enrollment criteria at the time — so the treatment team managed his condition through other means instead
The years between: his myeloma relapsed twice; his treatment plan was adjusted through remote/online consultation with the hospital's team to keep the disease in check
Why he came back: by the time a commercially approved BCMA CAR-T product became available, he chose to return to the same hospital for treatment — citing trust built over the earlier relationship with the team
The Medical Team & the Treatment
A top-ranked 3A-grade hospital in Xi'an — its Department of Hematology was among the earliest in China to establish a CAR-T cell therapy program, and has built what it describes as a regional blood-disease cell therapy center encompassing CAR-T, CAR-NK, and related therapies.
Dr. Liang Wei (pseudonym) — Deputy Director of the hospital's hematology department, who led the patient's care.
Dr. Song Mei and Dr. Tan Hui (pseudonyms), together with the hospital's hematology nursing team, carried out the treatment and post-infusion care.
The therapy itself: a BCMA (B-cell maturation antigen)-targeted CAR-T cell product — the patient's own T cells engineered to recognize and attack myeloma cells expressing BCMA on their surface, infused as a single treatment.
Why this hospital's history with this specific therapy matters: starting in 2016, the hospital partnered with a Chinese biotech company on a Phase 1 open-label clinical trial of a BCMA-targeted CAR-T product for relapsed/refractory multiple myeloma — one of four hospital sites nationwide running that first-in-human study. The trial produced strong enough results that the therapy earned Breakthrough Therapy Designation from the US FDA in 2019, and the same underlying CAR-T product has since gone on to full US regulatory approval as a commercial multiple myeloma treatment. This patient's 2024 treatment used the now-commercial version of that same therapy — meaning his case sits at the end of an eight-year arc from experimental trial to approved product, at the same institution.
Treatment Timeline
Date/Period | Milestone |
Years prior | Multiple myeloma diagnosed and treated domestically; disease recurs, quality of life declines |
2016 | Patient first travels to this hospital seeking CAR-T therapy; does not meet trial eligibility criteria at the time |
2016–2024 | Two disease relapses; treatment plan managed through periodic remote consultation with the hospital's hematology team |
April 8, 2024 | Commercial BCMA-targeted CAR-T cell infusion administered |
Following infusion | Symptoms and disease burden notably reduced |
After a period of follow-up | Multiple myeloma reported as effectively controlled, with significant improvement in the patient's overall health |
What This Case Reflects About CAR-T Access in China
This case illustrates something that's easy to miss when reading about a single successful treatment: access to CAR-T isn't always immediate, even at a hospital running one of the most established programs for a given disease. This patient's first attempt in 2016 didn't work out because he didn't meet trial criteria — a reminder that early-phase CAR-T trials have narrower eligibility windows than the commercially approved products that eventually follow them. What changed by 2024 was that the therapy had matured from an investigational trial into a licensed, commercially available product, widening who could realistically access it.
It also reflects something notable about international demand: this patient wasn't a domestic Chinese patient — he traveled from Kyrgyzstan specifically because this treatment wasn't available to him at home, and he chose to return to the same Chinese hospital he'd built a relationship with years earlier rather than seek treatment elsewhere. That's a pattern international patients researching CAR-T access should find informative: continuity of care with a specific hospital and team, sustained even across relapses and years, can matter as much as the underlying technology. For how to independently verify hospital quality before committing to a center, see our guide to JCI-accredited hospitals in China and their US academic partnerships.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
Reading This Case With the Right Caveats
"Effectively controlled" is not the same as cured. Multiple myeloma remains, for the large majority of patients, a disease that responds to treatment but is not currently curable — even strong CAR-T responses are typically followed by ongoing monitoring for eventual relapse, and the source reporting here doesn't include the more granular remission data (like MRD status or PET-CT findings) seen in some other CAR-T case reports.
This patient's two prior relapses are part of the story, not a footnote. His case underscores that CAR-T is often reached only after multiple prior lines of therapy have already failed, which is also when it tends to be used clinically.
For international patients and families evaluating multiple myeloma treatment or CAR-T therapy in China, see how ChinaCureLink coordinates CAR-T treatment in China — hospital selection, eligibility screening, and end-to-end coordination.
FAQ
What is BCMA CAR-T therapy, and how is it different from CD19 CAR-T?
BCMA (B-cell maturation antigen) CAR-T therapy targets a protein found on myeloma cells, making it specific to multiple myeloma — unlike CD19 CAR-T, which targets lymphomas and certain leukemias. Both use the same underlying approach of engineering a patient's own T cells to recognize and kill cancer cells expressing a specific surface marker.
Why didn't this patient qualify for CAR-T treatment when he first tried in 2016?
Early-phase clinical trials, like the one running at this hospital in 2016, have strict enrollment criteria (disease stage, prior treatment history, overall health, and more) designed to protect patient safety while the therapy is still investigational. Those criteria are typically narrower than the eligibility requirements for the same therapy once it becomes a commercially approved product.
Is multiple myeloma curable with CAR-T therapy?
Not currently, for most patients. CAR-T therapy can produce deep and sometimes durable remissions in relapsed/refractory multiple myeloma, but the disease is still considered incurable for the majority of patients, and ongoing monitoring after treatment is standard practice.
How long does BCMA CAR-T treatment take from decision to infusion?
Timelines vary by hospital and case, generally spanning several weeks for cell collection, manufacturing, and pre-treatment preparation — similar to CAR-T timelines for other blood cancers.
Where can I learn more about CAR-T cost and hospital options in China?
See our dedicated guide to BCMA CAR-T therapy for multiple myeloma in China, or our broader CAR-T for multiple myeloma 2026 guide.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.
Disclaimer
This article is for informational purposes only and does not constitute medical or financial advice. Treatment eligibility, protocols, and outcomes vary by individual patient and disease subtype. Please confirm specifics with a qualified oncologist or a ChinaCureLink coordinator before making treatment decisions.
References
"A 70-Year-Old Kyrgyz Man Successfully Received CAR-T Cell Therapy in China," DXY (丁香园) Hospital News, published May 29, 2024, y.dxy.cn/hospital/58/951288.html.
Zhao, W.-H. et al., "A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma," PubMed — LEGEND-2 trial, confirms the hospital's role as one of four Chinese trial sites since 2016.
"The China Center for Drug Evaluation... Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells)," BioSpace — corroborates FDA Breakthrough Therapy Designation (Dec. 2019) and the drug's later evolution into the FDA-approved product ciltacabtagene autoleucel (Carvykti).
Comments